David J. Bunyan

David J. Bunyan

Auto-generated profile, based on publicly available information

David J. Bunyan

Wessex Genomics Laboratory Service, Salisbury District Hospital, Salisbury, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2008 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MBMoira Blyth
Moira Blyth
NFNicola Foulds
Nicola Foulds
CTClaire Turner
Claire Turner
DBDavid Bunyan
David Bunyan

1 July 2020 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
ECEsther Cross
Esther Cross
PDPhilippa J. Duncan-Flavell
Philippa J. Duncan-Flavell
RHRachel J. Howarth
Rachel J. Howarth
RCRichard O. Crooks
Richard O. Crooks
NTN. Simon Thomas
N. Simon Thomas
DBDavid J. Bunyan
David J. Bunyan

21 August 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
ECEsther Cross
Esther Cross
PDPhilippa J. Duncan‐Flavell
Philippa J. Duncan‐Flavell
RHRachel J. Howarth
Rachel J. Howarth
JHJames I. Hobbs
James I. Hobbs
NTNicholas Simon Thomas
Nicholas Simon Thomas
DBDavid J. Bunyan
David J. Bunyan


13 January 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
KEKatharine Edgerley
Katharine Edgerley
ABAngela Barnicoat
Angela Barnicoat
AOAmaka C. Offiah
Amaka C. Offiah
ACAlistair D. Calder
Alistair D. Calder
KMKshitij Mankad
Kshitij Mankad
SSSarah F. Smithson
Sarah F. Smithson

10 March 2026 in European Journal of Human Genetics
Verified
Journal Article
Open access
COCarolina Jaramillo Oquendo
Carolina Jaramillo Oquendo
FFFederico Ferraro
Federico Ferraro
HWHtoo A. Wai
Htoo A. Wai
HFHeather Ferrao
Heather Ferrao
HLHerma van der Linde
Herma van der Linde
DBDiana Baralle
Diana Baralle
Splice-disrupting variants are estimated to account for one-third of disease-causing variants, yet many remain underrepresented in clinical databases due to limitations in detecting splicing changes beyond canonical splice sites. Short-read RNA sequencing (RNA-seq) has proved to be a valuable complement in clinical practice to address this gap, however, the added value of long-read RNA-seq is unclear. We evaluated the potential of PacBio long-read RNA-seq to detect pathogenic splicing events in rare disorders, comparing its performance to short-read RNA-seq. Participants from the UK ( n = 23) and the Netherlands ( n = 2) with suspected splice-altering variants underwent long-read RNA-seq following the Kinnex full-length RNA protocol. HiFi reads from the Revio instrument were processed using the Read Segmentation and Iso-Seq workflow and then classified and filtered using Pigeon. Detection of disease genes was comparable with short reads, with fibroblast capturing more transcripts overall. Novel isoforms accounted for ~14% of detected transcripts in both tissues, increasing following cycloheximide treatment in fibroblasts and decreasing following globin depletion in blood. Transcript abundance estimates showed strong concordance between short- and long-read platforms (Pearson r = 0.86 and 0.61 in blood and fibroblasts, respectively). LRS captured 21 confirmed known events, and revealed additional transcript-level effects in eight cases. This included intron retention, multiple exon skipping, leaky splicing, variant phasing, and isoform switching. These results demonstrate that long-read RNA-seq enhances detection and interpretation of clinically relevant splicing events, supporting its integration into diagnostic workflows for rare diseases.